drugset / Trial / NCT00844519
Effect of Maraviroc on Endothelial Function in HIV-Infected Patients
Phase 3
Completed
52 enrolled
University of California, San Francisco
National Heart, Lung, and Blood Institute (NHLBI) · collabPfizer · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the potentially beneficial aspects of CCR5 inhibition on inflammation and endothelial function as measured by brachial artery reactivity in antiretroviral treated HIV patients with an undetectable viral load.
Timeline
- Start
- 2010-01
- Primary completion
- 2012-12
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Maraviroc | Other / unclassified | 150 mg | Oral |
| Comparator | Maraviroc | Other / unclassified | 300 mg | Oral |